
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    To annotate the cell type based on the provided ranked marker list from a single-cell RNA sequencing dataset of breast cancer tissue, we will follow the outlined steps:<br><br>### Step 1: List the Key Functional Markers<br>- **LYZ (Lysozyme):** An enzyme that breaks down bacterial cell walls, commonly associated with myeloid cells, particularly macrophages and neutrophils.<br>- **TYROBP (DAP12):** An adaptor protein involved in immune signaling, often found in myeloid cells.<br>- **AIF1 (Allograft Inflammatory Factor 1):** Involved in inflammatory responses, typically expressed in macrophages and microglia.<br>- **FCER1G (Fc Fragment of IgE Receptor Ig):** Part of the receptor complex for IgE, expressed in various immune cells, including macrophages and dendritic cells.<br>- **C1QA, C1QB, C1QC:** Components of the complement system, primarily expressed in macrophages.<br>- **HLA-DRA, HLA-DPA1, HLA-DQA1, HLA-DPB1, HLA-DRB1, HLA-DRB5, HLA-DMA, HLA-DMB, HLA-DQB1:** Major histocompatibility complex class II molecules, crucial for antigen presentation, predominantly expressed in antigen-presenting cells like macrophages and dendritic cells.<br>- **CD14:** A co-receptor for the detection of bacterial lipopolysaccharide, highly expressed in monocytes and macrophages.<br>- **SPI1 (PU.1):** A transcription factor critical for myeloid and lymphoid lineage development, especially in macrophages and B cells.<br>- **APOE (Apolipoprotein E):** Involved in lipid metabolism, expressed in macrophages and other cell types.<br>- **CTSS (Cathepsin S):** A protease involved in antigen processing, expressed in antigen-presenting cells.<br><br>### Step 2: List the Key Cell Type Markers<br>- **CD68:** A glycoprotein highly expressed in macrophages, used as a marker for these cells.<br>- **CD74:** Involved in MHC class II antigen processing, expressed in antigen-presenting cells.<br>- **FPR3 (Formyl Peptide Receptor 3):** Expressed in monocytes and macrophages.<br>- **MS4A6A:** Part of the MS4A family, associated with immune cells, particularly macrophages.<br>- **CLEC7A (Dectin-1):** A pattern recognition receptor expressed in dendritic cells and macrophages.<br>- **ITGB2 (Integrin Beta 2):** Expressed in leukocytes, including macrophages and neutrophils.<br>- **CD83:** A marker for mature dendritic cells and activated macrophages.<br><br>### Step 3: Cross-reference Known Databases<br>Cross-referencing with databases such as the Human Cell Atlas, PanglaoDB, and literature on breast cancer tissue, the markers listed are predominantly associated with myeloid lineage cells, particularly macrophages and dendritic cells.<br><br>### Step 4: Determine the Most Probable General Cell Type<br>Based on the expression of these markers, the most likely general cell type is **macrophages**. This is supported by the high expression of markers like CD68, CD14, and various complement components.<br><br>### Step 5: Identify the Top 3 Most Probable Sub Cell Types<br>1. **Tumor-associated macrophages (TAMs):** Given the context of breast cancer tissue, TAMs are a likely subtype, characterized by markers such as CD68, CD14, and APOE.<br>2. **M1 Macrophages:** Pro-inflammatory macrophages, potentially indicated by the presence of markers like TNFSF13B and CCL3.<br>3. **M2 Macrophages:** Anti-inflammatory macrophages, possibly indicated by markers like APOE and FGL2.<br><br>The most likely subtype, considering the tumor environment, is **Tumor-associated macrophages (TAMs)**.<br><br>### Step 6: Provide a Concise Summary of Your Analysis<br>The analysis of the ranked marker list from the breast cancer tissue dataset suggests that the cell cluster is primarily composed of macrophages. The expression of key markers such as CD68, CD14, and various MHC class II molecules supports this annotation. Within the macrophage lineage, the most probable subtype is tumor-associated macrophages (TAMs), which play a significant role in the tumor microenvironment by modulating immune responses and promoting tumor progression.<br><br>**FINAL ANNOTATION COMPLETED**
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    Validation result: VALIDATION PASSED<br><br>The proposed annotation result is consistent with the provided marker list and the identified cell type. The markers listed in the annotation are present in the provided marker list, and they are appropriately associated with myeloid lineage cells, particularly macrophages and dendritic cells. The analysis correctly identifies macrophages as the primary cell type, with tumor-associated macrophages (TAMs) being the most probable subtype given the context of breast cancer tissue. The annotation process has been thorough, considering both general and specific markers, and cross-referencing with known databases supports the conclusions drawn. There is no strong evidence of mixed cell types that would necessitate further investigation.
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">macrophages</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>Tumor-associated macrophages (TAMs)</li><li>M1 Macrophages</li><li>M2 Macrophages</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li class="empty-list">No mixed cell types identified</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">90</div>
                        <div class="scoring-content">
                            The annotation results provided for the single-cell RNA sequencing dataset from breast cancer tissue are generally well-executed, with a strong focus on identifying macrophages as the primary cell type. The analysis effectively utilizes a wide range of markers, such as LYZ, TYROBP, and CD68, which are well-known to be associated with myeloid lineage cells, particularly macrophages. The identification of tumor-associated macrophages (TAMs) as the most probable subtype is appropriate given the context of breast cancer tissue, where TAMs are known to play a significant role in the tumor microenvironment.<br><br>The annotation process demonstrates a balanced consideration of multiple markers, rather than over-focusing on a specific one. For instance, the inclusion of both general macrophage markers (e.g., CD68, CD14) and more specific markers (e.g., APOE, FGL2) provides a comprehensive view of the cell types present. The analysis also appropriately considers the rank of the markers, with key markers like LYZ and TYROBP appearing early in the list, indicating their importance in the annotation process.<br><br>However, there are a few areas where the analysis could be improved. While the annotation correctly identifies macrophages as the primary cell type, it could have explored the potential presence of other immune cell types, such as dendritic cells, which are also suggested by some of the markers (e.g., CLEC7A, CD83). Additionally, the analysis could have provided more detail on the potential functional roles of the identified subtypes (e.g., M1 vs. M2 macrophages) in the context of breast cancer.<br><br>Overall, the annotation is scientifically accurate and provides a comprehensive view of the cell populations present in the dataset. There are no obvious misclassifications or oversights, and the analysis effectively captures the general picture of the data.<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    